SYNERGY AI

Based in Seoul, South Korea, SYNERGY AI Corp focuses on advanced healthcare technologies, specifically developing innovative measurement systems to enhance diagnostic accuracy for healthcare professionals. SYNERGY AI specializes in providing cutting-edge healthcare technology solutions, particularly in diagnostic measurement. Founded in 2018 in Seoul, South Korea, the company has undergone no significant pivots in its business strategy. The founder has not been publicly identified, and the company has not disclosed any parent or subsidiary relationships.

SYNERGY AI raised KRW 2 billion in its most recent funding round in May 2022, primarily from investors Daewoong Pharmaceutical, Evergreen Investment Partners, and WIDENPARTNERS, totaling KRW 2 billion raised so far from two deals. SYNERGY AI specializes in advanced healthcare technologies, focusing on innovative measurement techniques designed to enhance diagnostic precision. Their core offering includes the Ellipsoid measurement system, which utilizes a unique approach to provide accurate assessments of patient conditions. This system is tailored to healthcare professionals looking to improve patient outcomes through reliable diagnostics.

The primary end users of SYNERGY AI's products include hospitals, clinics, and medical practitioners across diverse geographical markets, including North America, Europe, and Asia. By addressing critical challenges in medical accuracy and efficiency, the company positions itself as a provider of solutions that elevate the standard of care. In 2021, SYNERGY AI reported a revenue of KRW 60,073. Following the recent funding round in May 2022, SYNERGY AI intends to utilize the KRW 2 billion raised to enhance its research and development efforts in signal processing and wearable devices.

The company's strategy includes designing new products aimed at improving healthcare diagnostics, with specific plans to expand its market presence into North America and Europe within the next two years.